Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of RDX5791 in Healthy Volunteers
Study Overview
Detailed Description
In the single-ascending dose (SAD), 5 separate cohorts received RDX5791 at various doses once po fasting. Each cohort of 8 subjects (6 RDX5791, 2 placebo) received a diet standardized fro Na+ content wile in the clinical pharmacology unit (CPU).
The PK data from the 50-mg dose and the safety data from the 150-mg dose of the SAD study were evaluated prior to proceeding with the multiple-ascending dose (MAD) phase. Doses of RDX5791 are 3, 10, 30, and 100 mg administered once daily po fasting. Four cohorts of 10 subjects each (8 RDX5791, 2 placebo) received a diet standardized for Na+ content while in the CPU.
Safety assessments including clinical assessment and vital signs, clinical laboratory evaluations, ECGs, and AE monitoring were performed at regular intervals. Plasma was collected at regular intervals for PK analysis. The PD assessment included stool frequency and consistency, as well as changes in urinary Na+ excretion. All bowel movements were collected and analyzed for Na+ content outside this study protocol.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI between 18 and 29.9 kg/m², inclusive
- Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception
- Males must agree to use appropriate methods of barrier contraception or have documented surgical sterilization
Exclusion Criteria:
- Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract
- Any surgery on the small intestine or colon, excluding appendectomy
- Loose stools (Bristol Stool Form Score of 6 or 7) ≥2 days in the past 7 days
- Hepatic dysfunction ([ALT] or [AST]) >1.5 times the upper limit of normal or renal impairment
- Any evidence of or treatment of malignancy, excluding non-melanomatous malignancies of the skin
- Use of diuretic medications, medications that are known to affect stool consistency and/or GI motility
- Use of an investigational agent within 30 days prior to Day -2
- Positive virology, alcohol, or drugs of abuse test during screening
- Use of any prescription medication within 7 days before admission to the CPU
- Have had significant blood loss (>450 mL) or have donated 1 or more units of blood or plasma within 8 weeks prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: RDX5791 10mg QD (SAD phase)
10mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 50mg QD (SAD phase)
50mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 150mg QD (SAD phase)
150mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 450mg QD (SAD phase)
450mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 900mg QD (SAD phase)
900mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 3mg QD (MAD phase)
3mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 10mg QD (MAD phase)
10mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 30 mg QD (MAD phase)
30mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
|
Experimental: RDX5791 100 mg QD (MAD phase)
100mg of RDX5791 administered once daily PO fasting
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: 7 days
|
serum chemistry and hematology, ECGs, and clinical signs and symptoms
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics of RDX5791
Time Frame: 7 days
|
blood levels of drug
|
7 days
|
|
Urinary and fecal sodium levels
Time Frame: 7 days
|
to assess the pharmacodynamics of RDX5791
|
7 days
|
|
Urinary and fecal phosphorus levels
Time Frame: 7 days
|
to assess the pharmacodynamics of RDX5791
|
7 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RDX5791-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.